IMR Press / EJGO / Volume 20 / Issue 5-6 / pii/1999192

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Case Report

Good response of malignant mixed mullerian tumor of the ovary to paclitaxel and cisplatin chemotherapy

Show Less
1 Division of Gynecolgic Oncology, The University of Vermont, Burlington, Vermont, USA
Eur. J. Gynaecol. Oncol. 1999, 20(5-6), 355–356;
Published: 10 October 1999

Survival of patients with advanced stage malignant mixed mullerian tumor of the ovary is poor and the best treatment remains unknown. A 62-year-old woman diagnosed with stage IIIC heterologous malignant mixed mullerian tumor of the ovary underwent optimal cytoreductive surgery followed by paclitaxel (135 mg/m2 over 24 hours) and cisplatin (75 mg/m2) every 4 weeks for 6 courses. The patient tolerated chemotherapy well, had complete clinical response and remained without disease for 21 months following diagnosis. Paclitaxel and cisplatin may be effective in malignant mixed mullerian tumors of the ovary.

Ovarian sarcoma
Back to top